Reporting mortality findings in trials of rofecoxib for Alzheimer disease or cognitive impairment: A case study based on documents from rofecoxib litigation

JAMA

Volumn 299, Issue 15, 2008, Pages 1813-1817

  Psaty, Bruce M ^a,c   Kronmal, Richard A ^b  

^a CENTER FOR HEALTH STUDIES   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; ROFECOXIB; CYCLOOXYGENASE 2 INHIBITOR; LACTONE; SULFONE;

ALZHEIMER DISEASE; CASE STUDY; CLINICAL TRIAL; COGNITIVE DEFECT; DRUG FATALITY; DRUG INDUSTRY; DRUG SAFETY; DRUG TOLERABILITY; FOOD AND DRUG ADMINISTRATION; HUMAN; LAW SUIT; MEDICAL INFORMATION; MORTALITY; PRIORITY JOURNAL; PUBLICATION; REVIEW; UNSPECIFIED SIDE EFFECT; ARTICLE; ETHICS; LEGAL ASPECT; PROFESSIONAL STANDARD; PUBLISHING; RISK; STANDARD; STATISTICAL ANALYSIS; UNITED STATES;

ALZHEIMER DISEASE; CLINICAL TRIALS AS TOPIC; CLINICAL TRIALS DATA MONITORING COMMITTEES; COGNITION DISORDERS; CYCLOOXYGENASE 2 INHIBITORS; DATA INTERPRETATION, STATISTICAL; DRUG INDUSTRY; ETHICS COMMITTEES, RESEARCH; HUMANS; LACTONES; MORTALITY; PUBLISHING; RISK; SULFONES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 42249100174     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.299.15.1813     Document Type: Review

References (25)

1. DeAngelis CD, Drazen JM, Frizelle FA, et al. Clinical trial registration: a statement from the International Committee of Medical Journal Editors. JAMA. 2004;292(11):1363-1364.
2. Food and Drug Administration Amendments Act of 2007. HR 3580, enacted by the House and Senate, Pub L No 110-85. http://frwebgate.access.gpo.gov/cgi-bin/ getdoc.cgi?dbname=110_cong_bills&docid=f:h3580enr.txt.pdf. Accessed October 11, 2007.
3. Piaggio G, Elbourne DR, Altman DG, Pocock SJ, Evans SWJ. Reporting of noninferiority and equivalence randomized trials. JAMA. 2006;295(10):1152-1160.
4. Fontanarosa PB, DeAngelis CD. Publication of clinical trials in JAMA: information for authors. JAMA. 2008;299:95-96.
5. Turner EH, Matthews A, Linardatos E, Tell R, Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med. 2008;358(3):252-260.
6. Humeston et al v Merck & Company, Inc. Case #619 in Superior Court of New Jersey, Atlantic County (September 23, 2005).
7. Bresalier RS, Sandler RS, Quan H, et al; APPROVe Trial Investigators. Cardiovascular events associated with rofecoxib in a 3-year randomized colorectal adenoma chemoprevention trial. N Engl J Med. 2005;352(11):1092-1102.
8. Kerr DJ, Dunn J, Langman M, et al; for the VICTOR Trial Group. Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer. N Engl J Med. 2007;357(4):360-369.
9. Thal LJ, Ferris SH, Korby L; Rofecoxib Protocol 078 Study Group. A randomized double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology. 2005;30(6):1204-1215.
10. Reines SA, Block GA, Morris JC, et al. Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study. Neurology. 2004;62(1):66-71.
11. Humeston et al v Merck & Company, Inc. Case #619 in Superior Court of New Jersey, Atlantic County. Plaintiff Exhibit Pl.0023, MRK-01420145856 (September 23, 2005). Safety Update Report.
12. Merck produced nonconfidential document. FDAWEB 000634, linked to MRK-AAF0005014.
13. Merck produced nonconfidential document. MRK-01420167265.
14. Humeston et al v Merck & Company, Inc. Case #619 in Superior Court of New Jersey, Atlantic County. Plaintiff Exhibit Pl.0079, MRK-AAAX0000752 (September 23, 2005).
15. Humeston et al v Merck & Company, Inc. Case #619 in Superior Court of New Jersey, Atlantic County. Plaintiff Exhibit 362, MRK-NJ0186457 (February 6, 2007).
16. Humeston et al v Merck & Company, Inc. Case #619 in Superior Court of New Jersey, Atlantic County. Defendant Exhibit D-1445, MRK-I8940079159 (February 6, 2007). Clinical study report.
17. In Re: Vioxx litigation, case code 619, civil action (ATL-L-2272-03). Filed January 13, 2006, in Superior Court of New Jersey, Atlantic County.
18. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA. 2001;286(8):954-959.
19. Konstam MA, Weir MR, Reicin A, et al. Cardiovascular thrombotic events in controlled clinical trials of rofecoxib. Circulation. 2001;104(19):2280-2288.
20. Office of the Inspector General. The Food and Drug Administration's oversight of clinical trials. Washington, DC: Dept of Health and Human Services; September 2007. http://oig.hhs.gov/oei/reports/oei-01-06-00160.pdf. Accessed October 3, 2007.
21. DeAngelis CD, Drazen JM, Frizelle FA, et al. Is this clinical trial fully registered? a statement from the International Committee of Medical Journal Editors. JAMA. 2005;293(23):2927-2929.
22. Korn D, Ehringhaus S. Principles for strengthening the integrity of clinical research. PLoS Clin Trials. 2006;1(1):e1. doi:10.1371/journal. pctr.0010001.
23. Shuchman M. Commercializing clinical trials - risks and benefits of the CRO boom. N Engl J Med. 2007;357(14):1365-1368.
24. Grassley CE. Letter to FDA. United States Senate Committee on Finance with additional back up data. December 13, 2006.
25. Ross DB. Testimony before the House Committee on Energy and Commerce, Subcommittee on Oversight and Investigations. February 13, 2007. http://energycommerce.house.gov/cmte_mtgs/110-oi_hrg.o21307.FDA_drug_supply. shtml.